Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

77.27 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
BridgeBio's Dwarfism Candidate Shows Favorable Height Increase, Safety Profile ↗
BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the... 
Via Benzinga
News headline image
What's Going On With Kala Pharmaceuticals Shares Today ↗
Kala Pharmaceutical (NASDAQ: KALA) shares skyrocketed more than 20% Monday morning on higher-than-average volume. On an average market day, Kala shares trade about 2.5 million times throughout the... 
Via Benzinga
News headline image
Kennedy-Wilson, Radian Group, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
What's Going On With Avalon GloboCare Shares Today ↗
The overall market ticked slightly higher in pre-market trading Monday morning, but Avalon Globocare Corp (NASDAQ: ALBT) shares really took off. Avalon GloboCare is a biotech company headquartered in... 
Via Benzinga
News headline image
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose... 
Via Benzinga
News headline image
Looking Into BridgeBio Pharma's Return On Capital Employed ↗
 
Via Benzinga
Looking Into BridgeBio Pharma's Return On Capital Employed ↗
 
Via Benzinga
News headline image
BridgeBio Pharma: Q3 Earnings Insights ↗
BridgeBio Pharma (NASDAQ:BBIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study ↗
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
News headline image
Why BridgeBio Pharma Stock Is Hitting New 52-Week Highs Monday ↗
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 study of 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder ↗
 
Via Benzinga
News headline image
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial ↗
 
Via Benzinga
News headline image
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma to Participate in February and March Investor Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023 ↗
 
Via Benzinga
News headline image
Why BridgeBio Pharma Stock Is Shooting Higher ↗
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret. What Else? 
Via Benzinga
News headline image
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. 
Via Benzinga
News headline image
BridgeBio Pharma to Participate in November Investor Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
From BridgeBio Pharma, Inc.
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.